Inspire Medical Systems (INSP) Q2 2026 Earnings Call Transcript

Inspire Medical Systems reported Q2 revenue of $200.6M, down 7.6% YoY, with adjusted diluted EPS at $0.14 versus $0.34 a year earlier, as coding and reimbursement disruptions drove an estimated ~$40M headwind in the quarter. Management raised full-year revenue guidance to $835M–$875M (up from prior outlook) and guided adjusted operating margin to 4%–6%, while reiterating significant coding/reimbursement pressure in Q3 with revenue forecast down 8%–10% YoY; full-year estimated coding/reimbursement impact remains $120M–$130M. The company launched Project Horizon, targeting ~$30M in annualized growth investment capacity through $20M–$25M of restructuring/impairment charges (with ~90% recognized in Q3) and ended Q2 with $415.2M in cash and investments and no debt.

Analysis

This is more a channel-friction story than a true demand collapse, but that distinction matters only if billing normalization actually sticks. Because a relatively small set of high-volume centers drives a disproportionate share of bookings, recovery can snap back quickly once confidence returns; the flip side is that a few regional payer quirks can keep the whole franchise under pressure longer than bulls expect. Near term, that leaves the stock hostage to administrative cleanup rather than underlying clinical demand.

The competitive read-through is quietly favorable for ResMed (RMD) and, to a lesser extent, any sleep-apnea therapy that requires less procedural friction. When patients and physicians face reimbursement uncertainty, the default is to stay on existing CPAP pathways, so deferred implant volumes can bleed share to the incumbent non-invasive market even if Inspire's long-term TAM is intact. The proposed facility reimbursement is a medium-term positive, but it does not matter until final rates are locked and the field believes claims will adjudicate cleanly.

Project Horizon is the main second-order risk: it may improve margins later, but the supply-chain consolidation also reduces redundancy at exactly the moment management wants to reaccelerate growth. That raises execution risk if volumes rebound faster than production can be requalified, and it makes the 2026/2027 bridge more dependent on flawless operating discipline. The bearish thesis is invalidated only if September/November deliver cleaner coding, final CMS rates near proposal, and a visible step-up in prior-auths and implants by Q4; otherwise this looks like a 2027 story being priced too early.

Key Decisions for Investors

• Short INSP on any post-earnings strength or via 1-3 month put spreads into the November CMS final-rate window; thesis is that Q3/Q4 fundamentals remain gated by reimbursement normalization, with upside capped until adjudication clears. Risk: a faster-than-expected channel reopen could squeeze the position.
• Pair trade: long RMD / short INSP for a 1-3 month relative-value expression of deferred procedures staying on CPAP while Inspire works through billing friction. Falsifier: evidence of sustained prior-auth recovery and implant reacceleration by October.
• Watch item, not a trade yet: if September CPT review or November CMS final rules come in cleaner than expected, cover bearish exposure and rotate to a neutral stance; that would shift the debate from 'temporary freeze' to 'share recovery.'
• Avoid chasing the 'Project Horizon' margin story until there is proof that cost savings are being redeployed into measurable patient-flow gains; otherwise the market may be paying for 2027 optionality too early.